TCT-429 A Randomized Trial Comparing a Novel Sirolimus-Eluting Bioresorbable Scaffold withEverolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease: Two-year Clinical Outcomes

Yaling Han,Guosheng Fu,Xiaozeng Wang,Kai Xu,Bo Xu

Journal of the American College of Cardiology（2018）

引用 0|浏览1

暂无评分

摘要

Previous report of the randomized trial has demonstratedthat the novelpoly-L-lactic acidNeoVas (Lepu Medical, Beijing, China)bioresorbable scaffolds (BRS) was non-inferior to cobalt-chromium everolimus-eluting stents (CoCr-EES)for 1-year target lesion failure in patients with noncomplex coronary

查看译文

关键词

coronary artery disease,sirolimus-eluting,witheverolimus-eluting,two-year

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要